Explore other Johns Hopkins Sites
Wilmer Eye Institute at Johns Hopkins
 
 
 
 
Wilmer Eye Institute
 

Aimee Broman

Aimee Broman

Aimee Teo Broman, M.A.
Assistant Professor

Contact info:
Wilmer Eye Institute, Room 131
600 North Wolfe Street
Baltimore, MD 21287

Phone: 410 614 2483
Fax: 410 955 0096
e-mail: aibroman@jhmi.edu

Education
M.A. in Statistics, University of California at Berkeley
B.S in Mathematics and B.S.E in Electrical Engineering, Walla Walla College

Research Interests
Current research includes estimating individual progression of glaucoma from population-based estimates of visual field damage.  My interests lie in applying appropriate statistical methods to ophthalmologic data.

Representative Publications

(1) Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.

(2) Kuo IC, Broman A, Pirouzmanesh A, Melia M. Is there an association between diabetes and keratoconus? Ophthalmology. 2006;113(2):184-190.

(3) Broman AT, Munoz B, Rodriguez J et al. The Impact of Visual Impairment and Eye Disease on Vision-Related Quality of Life in a Mexican-American Population: Proyecto VER. Invest Ophthalmol Vis Sci. 2002;43(11):3393-3398.

(4) Broman AT, Munoz B, West SK et al. Psychometric properties of the 25-item NEI-VFQ in a Hispanic population: Proyecto VER. Invest Ophthalmol Vis Sci. 2001;42(3):606-613.

(5) Broman AT, West SK, Munoz B et al. Divided Visual Attention as a Predictor of Bumping while Walking: The Salisbury Eye Evaluation. Invest Ophthalmol Vis Sci. 2004;45(9):2955-2960.

(6) Broman AT, Hafiz G, Munoz B et al. Cataract and barriers to cataract surgery in a US Hispanic population: Proyecto VER. Arch Ophthalmol. 2005;123(9):1231-1236.

 (7) Broman AT, Shum K, Munoz B et al. Spatial Clustering of Ocular Chlamydial Infection over Time following Treatment, among Households in a Village in Tanzania. Invest Ophthalmol Vis Sci. 2006;47(1):99-104.

 
 
 
 
Controversy Swirls Around Lucentis

Julia Haller, professor of ophthalmology at Johns Hopkins explains why controversy swirls around Lucentis, a new drug approved by the FDA for the treatment of macular degeneration.

About John Hopkins - Find Out More

Out-of-State and International Patients - Find Out More

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System, All rights reserved.

About Johns Hopkins Medicine | Patient Care | Education | Research | Health Information Library
Get Directions | Contact Us | Request an Appointment | Refer a Patient | Find a Doctor | Media Inquiries